[ad_1]
India has reported another record increase of 95,735 new coronavirus infections in 24 hours as the virus spreads beyond its major cities.
According to the country’s Health Ministry, the number of people known to be infected in India reached 4,465,863 on Thursday.
It has the second highest number of cases in the world behind the United States, where more than 6.3 million people are known to be infected.
The Health Ministry also reported 1,172 deaths in the last 24 hours, bringing the total deaths to 75,062.
READ MORE:
* Coronavirus: There are no restrictions on cards for Kiwis returning from India, despite 28 positive cases.
* Coronavirus: disinformation about Covid-19 ‘could block the passage to level 1’
* Coronavirus: Taj Mahal to Reopen Despite Increase in Covid Cases in India
* India and China exchange their first border shots in 45 years
Its death toll is the third highest in the world behind the United States and Brazil.
The ministry said the rise in new infections is due to the increase in daily tests which now exceeds one million.
However, experts warn that India’s outbreak is entering a more dangerous phase as the virus spreads to smaller towns and villages.
The Indian capital registered a record increase of 4,618 new cases in the last 24 hours with 19 deaths. New Delhi, Pune, Mumbai and Chennai are the worst affected cities in the country.
With the economy contracting to a record 23.9 percent in the April-June quarter, leaving millions out of work, Indian authorities have said they have no choice but to continue to reopen the economy.
Meanwhile, the Serum Institute of India maintained that the temporary halt to late-stage studies of AstraZeneca’s Covid-19 candidate vaccine would not affect the timing of vaccine trials in India.
Studies in several countries were stopped due to a “potentially unexplained” illness in a British recipient.
Indian authorities said they would review the disease report and evaluate information from initial human clinical trials in India.
Serum, the world’s largest vaccine manufacturer by volume, mass-produces the vaccine for low- and middle-income countries.